RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase trial is testing a new treatment called HBI0101 CAR-T for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and atta…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
Phase: PHASE1 • Sponsor: Hadassah Medical Organization • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cell therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new cell therapy called LCAR-F33S in 35 people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to attack the cancer. The main goals are to check safet…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
Phase: NA • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial is testing a new type of CAR-T cell therapy made from donated umbilical cord blood. The cells are designed to attack two targets (BCMA and CD19) on myeloma cancer cells. Up to 18 adults with relapsed or refractory multiple myeloma will receive the treatment…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
Phase: PHASE1 • Sponsor: Xi'an No.3 Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC